



CSD/SE/UFR/2024-25
January 24, 2025

To
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai - 400001

To
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Outcome of the Board Meeting

.....

Pursuant to Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at their meeting held today i.e. on January 24, 2025, has taken on record and approved Un-audited Standalone and Consolidated Financial Results of the Company along with review reports of the Statutory Auditors for the quarter & nine months ended December 31, 2024.

We are enclosing herewith the following documents:

- a) Un-audited Standalone and Consolidated Financial Results for quarter & nine months ended December 31, 2024.
- b) Limited Review Reports of Statutory Auditors of the Company on the financial results as mentioned above and
- c) News Release of our company

Update on patents during this period are accessible to everyone at below mentioned web link: www.suven.com/Patentupdates.aspx

We request you to take these documents on your records. The Board Meeting commenced at 03:15 P.M. and concluded at 03:50 P.M.

Thanking you.
Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Company Secretary & Compliance Officer
FCS 12400

Encl.: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com




SUVEN LIFE SCIENCES LTD

Off:SDE Serene Chambers,6th floor, Road No.5, Banjara Hills, Hyderabad - 500 034

STATEMENT OF UN AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31, 2024.

Rs. In Lakhs							
STANDALONE							
Sl. No.	PARTICULARS	For the Quarter Ended			For the Nine Months period ended		For the year ended
		31/12/2024	30/09/2024	31/12/2023	31/12/2024	31/12/2023	31/03/2024
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	160.99	257.29	245.08	518.88	930.77	1,169.29
	Other Income	156.93	403.48	606.56	953.51	1,684.69	2,113.00
	Total income	317.92	660.77	851.64	1,472.39	2,615.46	3,282.29
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	486.58	520.34	432.04	1,475.88	1,307.02	1,653.37
	d) Finance costs	0.79	1.56	3.54	4.66	12.85	15.84
	e) Depreciation and amortisation expense	153.35	145.51	160.09	447.50	499.18	650.22
	f) R & D Expenses	826.49	908.96	618.85	2,194.43	1,621.28	2,038.87
	g) Other Expenses	177.90	191.59	114.00	550.89	409.23	570.72
	Total expenses	1,645.11	1,767.96	1,328.52	4,673.36	3,849.56	4,929.02
3	Profit before exceptional items & Tax (1-2)	(1,327.19)	(1,107.19)	(476.88)	(3,200.97)	(1,234.10)	(1,646.73)
4	Exceptional Items	-	-	-	-	745.66	745.66
5	Profit before Tax (3-4)	(1,327.19)	(1,107.19)	(476.88)	(3,200.97)	(488.44)	(901.07)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-	(100.24)
7	Net Profit/ (Loss) for the period/year(5-6)	(1,327.19)	(1,107.19)	(476.88)	(3,200.97)	(488.44)	(800.83)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(0.45)	(0.45)	4.75	(1.35)	14.24	(6.00)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(0.45)	(0.45)	4.75	(1.35)	14.24	(6.00)
9	Total Comprehensive Income for the period (7+8)	(1,327.64)	(1,107.64)	(472.13)	(3,202.32)	(474.20)	(806.83)
10	Paid-up equity share capital	2,180.74	2,180.74	2,180.74	2,180.74	2,180.74	2,180.74
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity						82,356.88
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(0.61)	(0.51)	(0.22)	(1.47)	(0.22)	(0.37)
	b) Diluted	(0.61)	(0.51)	(0.22)	(1.47)	(0.22)	(0.37)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the Nine Months period ended		For the year ended
		31/12/2024	30/09/2024	31/12/2023	31/12/2024	31/12/2023	31/03/2024
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
		(1)	(2)	(3)	(4)	(5)	(6)
1	Income						
	Revenue from operations	160.99	257.29	245.08	518.88	930.77	1,169.29
	Other Income	163.05	403.56	606.56	967.44	1,684.69	2,113.00
	Total Income	324.04	660.85	851.64	1,486.32	2,615.46	3,282.29
2	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	486.58	520.34	579.37	1,475.88	1,552.27	1,898.75
	d) Finance costs	0.79	1.56	3.54	4.66	12.85	15.84
	e) Depreciation and amortisation expense	153.35	145.51	160.29	447.50	499.38	650.22
	f) R & D Expenses	3,413.32	4,758.49	4,162.19	10,663.68	8,690.55	11,442.72
	g) Other Expenses	181.66	199.33	122.74	574.61	459.63	628.29
	Total expenses	4,235.70	5,625.23	5,028.13	13,166.33	11,214.68	14,635.82
3	Profit before exceptional items , Tax (1-2)	(3,911.66)	(4,964.38)	(4,176.49)	(11,680.01)	(8,599.22)	(11,353.53)
4	Exceptional Items	-	-	-	-	745.66	745.66
5	Profit before Tax (3-4)	(3,911.66)	(4,964.38)	(4,176.49)	(11,680.01)	(7,853.56)	(10,607.87)
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-	(100.24)
7	Net Profit/ (Loss) for the period/year(5-6)	(3,911.66)	(4,964.38)	(4,176.49)	(11,680.01)	(7,853.56)	(10,507.63)
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(0.45)	(0.45)	4.75	(1.35)	14.24	(6.00)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(0.45)	(0.45)	4.75	(1.35)	14.24	(6.00)
9	Total Comprehensive Income for the period (7+ 8)	(3,912.11)	(4,964.83)	(4,171.74)	(11,681.36)	(7,839.32)	(10,513.63)
10	Paid-up equity share capital Face Value of the Share	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00	2,180.74 Re.1.00
11	Other Equity	-	-	-	-	-	24,823.32
12	Earning Per Share (EPS) (Face value of Rs.1/- each) :						
	a) Basic	(1.79)	(2.27)	(1.92)	(5.36)	(3.60)	(4.82)
	b) Diluted	(1.79)	(2.27)	(1.92)	(5.36)	(3.60)	(4.82)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



NOTES:-

- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 24, 2025 . The results for the quarter ended December 31, 2024 has been reviewed by our statutory auditors
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the wholly Owned Subsidiary, Suven Neurosciences , Inc
- 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 5) The Company has allotted 7,26,91,239 equity shares amounting to Rs.39,980.18 lakhs through rights issue on November 16,2022.

Summary of Utilisation of Proceeds of Rights issue

Particulars	Amount Rs.In lakhs
Amout Raised through Rights Issue of Shares	39,980.18
Less: Rights Issue Expenses	(280.00)
Less: Amount Utilised	(37,490.74)
Balance Amount	2,209.44

6) The Company implemented SLSL Employee Stock Option Scheme 2020 ("ESOP") for eligible employees, which provides for the issuance of 10,00,000 options, each option convertible into one equity share. Out of these, 6,20,000 options were granted by the Nomination & Remuneration Committee on May 6, 2024. For the period ended December 31, 2024, the employee benefit expense includes a charge of ₹75.37 Lakhs in respect of equity-settled share-based payment transactions, in accordance with Ind AS 102 - 'Share-based Payment'.

7) The corresponding previous period figures have been regrouped / reclassified where ever necessary.

Place : Hyderabad
Date : January 24, 2025



For SUVEN LIFE SCIENCES LTD

Venkata Jasti
VENKAT JASTI
Chairman & MD
DIN: 00278028

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED
STANDALONE FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF
SUVEN LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SUVEN LIFE SCIENCES LIMITED**, having registered office at 6th Floor, SDE Serene Chambers, Road No 5, Banjara Hills, Hyderabad-500034, Telangana, for the quarter and nine months ended December 31, 2024 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation') as amended.

2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KARVY & CO.,
Chartered Accountants
(Firm Registration No .001757S)


DEDEE PYA NALLURI
Partner

M.No. 225106
UDIN: 25225106BM08YI4373



Place: Hyderabad
Date: January 24, 2025

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM UNAUDITED
CONSOLIDATED FINANCIAL RESULTS**

To
The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SUVEN LIFE SCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2024 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation')

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

Name of the Company	Relationship
Suven Life Sciences Limited	Parent
Suven Neuro Sciences Inc	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies

24/01/2025




Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of the subsidiary included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. Nil, and Rs. Nil for the quarter ended and nine months period ended December 31, 2024 and total net loss after tax of Rs. (2,584.48) lakhs and Rs.(8,479.05) Lakhs for the quarter ended and nine months period ended December 31, 2024, and total comprehensive income of Rs. (2,584.48) Lakhs and Rs. (8,479.05) Lakhs for the quarter ended and nine months period ended December 31, 2024 as considered in the Statement. This interim financial information has been reviewed by other auditor whose report have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on the reports of the other auditor.

Our conclusion on the statement is not modified in respect of the above matters.

For KARVY & CO.,
Chartered Accountants
(Firm Registration No .001757S)


DEDEEPPYA NALLURI
Partner
M.No. 225106
UDIN: 25225106BM08YJ9361



Place: Hyderabad
Date: January 24, 2025

24/01/2025



News Release

HYDERABAD, INDIA (24 Jan 2025) -- SUVEN Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter ended 31 December 2024. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 24 January 2025 at Hyderabad.

CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			Period ended		Year ended
	31-Dec-24	30-Sep-24	31-Dec-23	31-Dec-24	31-Dec-23	31-Mar-24
Revenue	32.40	66.09	85.16	148.63	261.55	328.23
R&D and Operational expenses	408.16	547.82	486.43	1,271.42	1,070.25	1,396.98
Depreciation and Amortisation	15.34	14.55	16.03	44.75	49.94	65.02
Finance cost	0.08	0.16	0.35	0.47	1.29	1.58
Total expenses	423.57	562.52	502.81	1,316.63	1,121.47	1,463.58
Exceptional items (insurance claim received)	-	-	-	-	74.57	74.57
Tax	-	-	-	-	-	(10.02)
Profit/(Loss) After Tax for the period/year	(391.17)	(496.44)	(417.65)	(1,168.00)	(785.36)	(1,050.76)
Other comprehensive income	(0.05)	(0.05)	0.48	(0.14)	1.42	(0.60)
Total comprehensive income	(391.21)	(496.48)	(417.17)	(1,168.14)	(783.93)	(1,051.36)
Paid up equity capital	218.07	218.07	218.07	218.07	218.07	218.07
Earnings per share of Rs.1 each (EPS)	(1.79)	(2.27)	(1.92)	(5.36)	(3.60)	(4.82)

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of FY26.
- SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy in Q1-FY26.
- SUVN-911 (Ropanicant) – Phase 2A open label study for Major Depressive Disorder in USA successfully completed. Preparing to start Phase 2B clinical study in Q1-FY26.
- SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition in MDD during FY26.
- SUVN-I6107 – Phase 1 study initiated during FY25 is continuing for establishing safety and pharmacokinetics of the molecule.

[For more information on Suven please visit our Web site at http://www.suven.com](http://www.suven.com)

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.

CIN: L24110TG1989PLC009713

6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India

Tel: 9140 2354 1142 / 1152 Email: info@suven.com